WST Stock Recent News
WST LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, with dividends from $1K invested meeting or exceeding their single share prices.
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy.
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.
EXTON, Pa. , March 5, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 11:00 AM ET. It will also present at the KBCM Healthcare Forum on Wednesday, March 19, 2025 at 1:30 PM ET.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.